Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHBD3T)

• Drug Name: SBT6050 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMHBD3T

Molecule-Related Drug Atlas

Drug(s) Targeting Erbb2 tyrosine kinase receptor (HER2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[3]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[4]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[5]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[6]
NERATINIB MALEATE	DMEDU7B	HER2/NEU overexpressing breast cancer	2C60-2C65	Approved	[7]
Margetuximab	DMKEY6S	HER2-positive breast cancer	2C60-2C65	Approved	[8]
Trastuzumab	DMZQOUX	Breast cancer	2C60-2C65	Approved	[9]
Tucatinib	DMBESUA	HER2-positive breast cancer	2C60-2C65	Approved	[10]
Pertuzumab	DMHJV0X	Adrenal gland neoplasm		Approved	[11]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[12]

Drug(s) Targeting Toll-like receptor 8 (TLR8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Resiquimod	DML6XSP	Actinic keratosis	EK90.0	Phase 2	[13]
Selgantolimod	DMST4OR	Hepatitis B	1E51	Phase 2	[14]
Afimetoran	DM3HN3U	Systemic lupus erythematosus	4A40.0	Phase 2	[15]
NKTR-262	DMYR8LF	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[16]
CPG 52364	DMVDYTG	Systemic lupus erythematosus	4A40.0	Phase 1	[17]
CV8102	DMYD37G	Melanoma	2C30	Phase 1	[18]
MEDI9197	DM0J7UR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[19]
VTX-1463	DM4ZIRK	Allergic rhinitis	CA08.0	Phase 1	[20]
DN1508052	DM0JT9C	Solid tumour/cancer	2A00-2F9Z	Phase 1	[21]
GSK5251738	DM8Y6DR	Hepatitis B	1E51	Phase 1	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erbb2 tyrosine kinase receptor (HER2)	TT6EO5L	ERBB2_HUMAN	Not Available	[2]
Toll-like receptor 8 (TLR8)	TT8CWFK	TLR8_HUMAN	Agonist	[2]

References

• [1] ClinicalTrials.gov (NCT04460456) A Study of SBT6050 Alone and in Combination With Pembrolizumab in Patients With Advanced HER2 Expressing Solid Tumors. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Silverback Therapeutics.
• [3] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
• [5] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [6] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [7] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [9] Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [11] Clinical pipeline report, company report or official report of Roche (2009).
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [13] TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70.
• [14] Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B. J Med Chem. 2020 Sep 24;63(18):10188-10203.
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [16] Clinical pipeline report, company report or official report of Nektar Therapeutics.
• [17] Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007.
• [18] Clinical pipeline report, company report or official report of CureVac.
• [19] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [20] VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs. 2011 Jul;20(7):981-6.
• [21] Clinical pipeline report, company report or official report of Shanghai De Novo Pharmatech.
• [22] Clinical pipeline report, company report or official report of GlaxoSmithKline